Amphastar Pharmaceuticals (AMPH) - Cash per Share

Amphastar Pharmaceuticals dominates the complex inhalation and injectable segment, leveraging low mass-production costs. The current cash per share confirms financial strength, as the parameter has stabilized at 5.46. This stability is bolstered by the development of biosimilars and innovative drug delivery systems, as well as operating leverage that significantly reduces costs as production volumes increase.
Analytical breakdowns for Amphastar Pharmaceuticals

To objectively assess the operational efficiency of Amphastar Pharmaceuticals (AMPH), investors must understand the actual volume of liquidity available for business development. By analyzing the cash per share metric via the GURU.Markets platform, you can see the ratio of cash holdings to the number of shares, which confirms the company's ability to fund expansion within the complex injectable drug niche and maintain margins when acquiring new brands.